A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors
NCT00721669 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2013-09-13
Summary
Primary objective is to evaluate the safety and PK of IMGN388
Conditions
Interventions
- DRUG
-
IMGN388
IMGN388 is a human IgG1 anti-integrin antibody conjugated to the maytansinoid, DM4.
Sponsors & Collaborators
-
ImmunoGen, Inc.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-06-30
- Primary Completion
- 2012-10-31
- Completion
- 2012-12-31
Countries
- United States
Study Locations
More Related Trials
-
A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors
NCT02298387 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of HG381 Administered to Patients With Advanced Solid Tumors
NCT04998422 ·Status: RECRUITING ·Phase: PHASE1
-
A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors
NCT00813384 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of IMP4297 in Patients With Advanced Solid Tumors
NCT03508011 ·Status: COMPLETED ·Phase: PHASE1
-
A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors
NCT01608867 ·Status: COMPLETED ·Phase: PHASE1
-
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
NCT05142592 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors
NCT01760525 ·Status: COMPLETED ·Phase: PHASE1
-
A Dose-escalation Study in Subjects With Advanced Malignancies
NCT01195311 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors
NCT06685068 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
NCT02923349 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
TSN222 in Subjects With Advanced Solid Tumors or Lymphomas
NCT05842785 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study Evaluating CMD-193 in Advanced Malignant Solid Tumors
NCT00161642 ·Status: COMPLETED ·Phase: PHASE1
-
Study of XL820 in Adults With Solid Tumors
NCT00129571 ·Status: COMPLETED ·Phase: PHASE1
-
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
NCT01004224 ·Status: COMPLETED ·Phase: PHASE1
-
Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors
NCT00305084 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4
NCT01409135 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation
NCT01915498 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of NK012 in Patients With Refractory Solid Tumors
NCT00542958 ·Status: COMPLETED ·Phase: PHASE1
-
A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors
NCT00743067 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
NCT02073994 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors
NCT01168011 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors
NCT04747470 ·Status: TERMINATED ·Phase: PHASE1
-
Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects
NCT01359982 ·Status: COMPLETED ·Phase: PHASE1
-
Study of INCB086550 in Select Solid Tumors
NCT04629339 ·Status: TERMINATED ·Phase: PHASE2
-
Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors
NCT02225002 ·Status: COMPLETED ·Phase: PHASE1